AndreaBozzo/ceres-open-data-index huggingface dataset:
Alternative flame retardants and polybrominated diphenyl ethers in ringed seals (Phoca hispida) across the Canadian Arctic

Concentrations of alternative flame retardants and polybrominated diphenyl ethers (PBDEs) were analyzed in ringed seal (Phoca hispida) blubber collected across the Canadian Arctic during subsistence hunts between 1998 and 2013. The presence of flame retardants in ringed seals suggests their persistence and their continuous inputs in the Canadian Arctic environment. Monitoring and research on the effects of these contaminants in seals are warranted given the importance of this species in Arctic marine food webs and for local communities.

Supplemental Information

The Northern Contaminants Program (NCP, http://www.science.gc.ca/eic/site/063.nsf/eng/h_7A463DBA.html) was established in 1991 in response to concerns about human exposure to elevated levels of contaminants in wildlife species that are important to the traditional diets of northern Aboriginal peoples. Early studies found a wide variety of substances, many of which had no Arctic or Canadian sources, but which were, nevertheless, reaching unexpectedly high levels in the Arctic ecosystem.

The Canadian Cryospheric Information Network (CCIN, https://www.ccin.ca/) and the Polar Data Catalogue (PDC, https://polardata.ca/) have been developed over the past two decades through collaborative partnerships between the University of Waterloo and numerous government, university, and private organizations to provide the data and information management infrastructure for the Canadian cryospheric community. The PDC is one of Canada’s primary online sources for data and information about the Arctic and is Canada's National Antarctica Data Centre.

Polar Data Catalogue Canadian Cryospheric Information Network Metadata Record:

https://www.polardata.ca/pdcsearch/PDCSearch.jsp?doi_id=10780 

Organization: Environment and Climate Change Canada | Environnement et Changement climatique Canada
Northern Hemisphere Blended Snow Extent and Snow Mass Time Series

This paper presents an analysis of observed and simulated historical snow cover extent and snow mass, along with future snow cover projections from models participating in the 6th phase of the World Climate Research Programme Coupled Model Inter-comparison Project (CMIP6). Where appropriate, the CMIP6 output is compared to CMIP5 results in order to assess progress (or absence thereof) between successive model generations. An ensemble of six observation-based products is used to produce a new time series of historical Northern Hemisphere snow extent anomalies and trends; a subset of four of these products is used for snow mass. Trends in snow extent over 1981-2018 are negative in all months, and exceed -50 x 103 km2 during November, December, March, and May. Snow mass trends are approximately -5 Gt/year or more for all months from December to May. Overall, the CMIP6 multi-model ensemble better represents the snow extent climatology over the 1981-2014 period for all months, correcting a low bias in CMIP5. Simulated snow extent and snow mass trends over the 1981-2014 period are stronger in CMIP6 than in CMIP5, although large inter-model spread remains in the simulated trends for both variables. There is a single linear relationship between projected spring snow extent and global surface air temperature (GSAT) changes, which is valid across all scenarios. This finding suggests that Northern Hemisphere spring snow extent will decrease by about 8% relative to the 1995-2014 level per °C of GSAT increase. The sensitivity of snow to temperature forcing largely explains the absence of any climate change pathway dependency, similar to other fast response components of the cryosphere such as sea ice and near surface permafrost.

Supplemental Information

The data in these four files are described in Mudryk et al. (2020).

1. monthly NH snow mass over the 1981-2018 time period based on estimates from MERRA2, Crocus, Brown, and GlobSnow.

2. monthly NH snow extent over the 1967-2018 time period based on estimates from NOAA Snow Chart record, JASMES, MERRA2, Crocus, Brown, and GlobSnow.

3. March snow extent based on Brown (2000) recalibrated to match 2.

4. April snow extent based on Brown (2000) recalibrated to match 2.

A full description of the analysis is contained in Mudryk et al. 2020

References:

Brown, R. D.: Northern Hemisphere snow cover variability and change, 1915–1997, J. Climate, 13, 2339–2355, 2000.

Mudryk, L., Santolaria-Otín, M., Krinner, G., Ménégoz, M., Derksen, C., Brutel-Vuilmet, C., Brady, M., and Essery, R.: Historical Northern Hemisphere snow cover trends and projected changes in the CMIP-6 multi-model ensemble, The Cryosphere Discuss., https://doi.org/10.5194/tc-2019-320, in review, 2020. 

Organization: Environment and Climate Change Canada | Environnement et Changement climatique Canada
2016 population ecumene by census subdivision

A population ecumene is the area of inhabited lands or settled areas generally delimited by a minimum population density. This ecumene shows the areas of the densest and most extended population within census subdivisions.   
  
  A census subdivision (CSD) is the general term for municipalities (as determined by provincial or territorial legislation) or areas treated as municipal equivalents for statistical purposes (e.g., Indigenous Peoples reserves and communities and unorganized territories). Municipal status is defined by laws in effect in each province and territory in Canada. For further information, consult the Statistics Canada’s 2016 Illustrated Glossary (see below under Data Resources).  
  
  The assemblage of dissemination block population density data from the 2016 Census of Population are used to form the ecumene areas within census subdivisions. Areas included in the ecumene are dissemination blocks where the population density is greater than or equal to 0.4 persons per square kilometre or about one person per square mile. In some areas to capture more population within the ecumene the criteria was extended to 0.2 persons per square kilometre. The ecumene areas were generalized in certain areas to remove small uninhabited areas within the ecumene areas in census subdivisions.  
  
  This map can be used as an “ecumene” overlay to differentiate the sparsely populated areas from the ecumene in conjunction with census subdivision data or other large-scale maps. This ecumene shows a more meaningful distribution of the population for Canada.

Organization: Natural Resources Canada | Ressources naturelles Canada
2016 population ecumene by census division

A population ecumene is the area of inhabited lands or settled areas generally delimited by a minimum population density. This ecumene shows the areas of the densest and most extended population within census divisions.   
  
  Census divisions are the provincially legislated areas (such as county, municipalité régionale de comté, and regional district) or their equivalents. Census divisions are intermediate geographic areas between the province or territory level and the municipality (census subdivision). For further information, consult the Statistics Canada’s 2016 Illustrated Glossary (see below under Data Resources).  
  
  The assemblage of dissemination area population density data from the 2016 Census of Population are used to form the ecumene within census divisions. Areas included in the ecumene are dissemination areas where the population density is greater than or equal to 0.4 persons per square kilometre or about one person per square mile. In some areas to capture more population within the ecumene the criteria was extended to 0.2 persons per square kilometre. The ecumene areas were generalized in certain areas to enhance the size of some isolated ecumene areas in northern Canada.  
  
  This map can be used as an “ecumene” overlay to differentiate the sparsely populated areas from the ecumene in conjunction with census division data or other small-scale maps. This ecumene shows a more meaningful distribution of the population for Canada.

Organization: Natural Resources Canada | Ressources naturelles Canada
Data collected under the Benzene in Gasoline Regulations

This collection of data summarizes the companies and facilities reporting under the Benzene in Gasoline Regulations. This data set includes total fuel volumes, benzene contents, benzene emission numbers, and companies reporting production and/or importation of gasoline. Additional gasoline parameters and properties are also found in this data set. The information was provided to Environment and Climate Change Canada under the Canadian Environmental Protection Act, 1999.

Organization: Environment and Climate Change Canada | Environnement et Changement climatique Canada
2016 population ecumene

A population ecumene is the area of inhabited lands or settled areas generally delimited by a minimum population density. Two population data sets from the 2016 Census of Population were used to build two specialized ecumene maps. The census division ecumene was built from dissemination area population density data and the census subdivision ecumene was built from the dissemination block population density data. For information on census divisions, census subdivisions, dissemination areas, and dissemination blocks consult the Statistics Canada’s 2016 Illustrated Glossary (see below under Data Resources).  
  
  Areas included in the ecumene (for either the census division or census subdivision) are areas where the population density is greater than or equal to 0.4 persons per square kilometre or about 1 person per square mile. In some areas to capture more population within the ecumene the criteria was extended to 0.2 persons per square kilometre. The ecumene areas were generalized in certain regions either to enhance the size of some isolated ecumene areas or to remove small internal uninhabited areas within the ecumene.  
  
  Either of these ecumene resources can be used as an “ecumene” map overlay to differentiate the sparsely populated areas from the ecumene in conjunction with the appropriate census geography or other small-scale and large-scale maps.

Organization: Natural Resources Canada | Ressources naturelles Canada
Investigation report : Mark Aldridge, President & CEO, MCAP Commercial LP

This report follows an investigation conducted by the Office of the Commissioner of Lobbying (OCL) pursuant to section 10.4 of the Lobbing Act (Act). This investigation focused on whether Mr. Mark Aldridge, President and CEO of MCAP Commercial LP (MCAP) and senior officer responsible for MCAP, failed to register in-house (corporation) lobbying activities in accordance with subsection 7(1) of the Act. This investigation arose in connection with communications that Mr. Robert Silver, Senior Vice-President of Strategy, Risk and Policy for MCAP, had with federal public office holders with respect to both MCAP’s role in administering the Canada Emergency Commercial Rent Assistance program on behalf of the Government of Canada as well as the eligibility of limited partnerships, such as MCAP, to claim the Canada Emergency Wage Subsidy (CEWS) in respect of their employees.

Organization: Office of the Commissioner of Lobbying of Canada | Commissariat au lobbying du Canada
Topographic Data of Canada - CanVec 1:50,000, 1944-2013

This collection is a legacy product that is no longer maintained. It may not meet current government standards. Users of Topographic Data of Canada - CanVec 1:50,000 (release 2013) should plan to make the transition towards the product [Topographic Data of Canada - CanVec Series](https://ouvert.canada.ca/data/en/dataset/8ba2aa2a-7bb9-4448-b4d7-f164409fe056).  
  
  CanVec contains more than 60 topographic features classes organized into 8 themes: Transport Features, Administrative Features, Hydro Features, Land Features, Manmade Features, Elevation Features, Resource Management Features and Toponymic Features.  
  
  This product originates from the best available geospatial data sources covering Canadian territory. It offers quality topographic information in vector format complying with international geomatics standards.  
  
  CanVec can be used in a geographic information systems (GIS) applications and used to produce thematic maps

Organization: Natural Resources Canada | Ressources naturelles Canada
Grid Areas of the Canada Oil and Gas Land Regulations

The land division system used for describing the extent of oil and gas interests located in the Northwest Territories, Nunavut or in Canada's offshore area is defined in the Canada Oil and Gas Land Regulations. This land division system consists of a grid system divided into Grid Areas, Sections, and Units – all referenced to the North American Datum of 1927 (NAD27).  This data provides the geo-spatial representation of the NAD27 Oil and Gas Grid Areas referenced to NAD83 Datum. The creation of the Oil and Gas Grid Areas geo-spatial file covers areas that are situated in the Northwest Territories, Nunavut or Sable Island as well as submarine areas, not within a province, in the internal waters of Canada, the territorial sea of Canada or the continental shelf of Canada beyond 200 nm zone. The NAD83 grid area boundaries are defined by geodesics joining the four grid area corners. For sections and units, the eastern and western grid area geodesic boundaries are partitioned into 40 equal segments. The northern and southern grid area geodesic boundaries are partitioned into 40, 32 or 24 equal segments, depending on latitude. All internal corners at the section and unit level are defined by the intersections of north-south and east-west geodesics joining corresponding partition points along the northern and southern, and eastern and western, grid area geodesic boundaries.

Organization: Natural Resources Canada | Ressources naturelles Canada
Guidance Document: Master Files for Veterinary Products: Procedures and Administrative Requirements

The objective of this guidance document is to outline the procedures that veterinary Master File (MF) holders must follow to file confidential business information (CBI) directly with Health Canada's Veterinary Drugs Directorate (VDD) that is cross-referenced in support of an Applicant's veterinary drug submission (including DIN (Drug Identification Number) applications.)

Organization: Health Canada | Santé Canada
Guidance for Industry Preparation of Veterinary New Drug submissions

This Guidance Document is to be used in the preparation of Veterinary Drug Submissions for presentation to Health Canada. Some sections of this Guidance Document are general in nature. Therefore, this Guidance Document should be used in conjunction with the complete Food and Drugs Act and Regulations, and with specific Health Canada Policies and Guidance Documents applicable to veterinary drugs. 

Organization: Health Canada | Santé Canada
Guidance for Industry - Preparation of Veterinary Abbreviated New Drug Submissions - Generic Drugs

This guidance document is intended to provide sponsors with an outline of the chemistry and manufacturing, clinical, and human safety requirements for the filing of the following submission types with the Veterinary Drugs Directorate (VDD): Abbreviated New Drug Submission (ANDS); Changes to ANDS - Supplemental Abbreviated New Drug Submission (SANDS) and Notifiable Change (NC).

Organization: Health Canada | Santé Canada
Guidance document on classification of veterinary drugs and livestock feeds

The purpose of this guidance document is to present guidelines and criteria for classification in order to clarify the differences between drugs and feeds, and to assist in determining the appropriate regulatory oversight for a product destined for use in livestock species. The pursued objectives are: to improve the transparency of the classification process, to increase the consistency in decisions by regulators, and make these more predictable to stakeholders; and to resolve industry confusion and to provide better guidance to manufacturers of such products regarding the appropriate regulatory department, submissions and processes for a product approval.

Organization: Health Canada | Santé Canada
Notice: Submission Filing Requirements - Good Manufacturing Practices (GMP)/Drug Establishment Licences (DEL)

Evidence of Good Manufacturing Practices (GMP) for drug submissions. The goal of this revision is to better align the drug submission screening and review process with the Drug Establishment Licence (DEL) process. This should allow sponsors to make timely drug submissions while still providing adequate assurance of an establishment’s commitment to quality.

Organization: Health Canada | Santé Canada
Appearance by the Honourable Steven Guilbeault before the Standing Committee on Canadian Heritage, study of Bill C-10, An Act to amend the Broadcasting Act and to make related and consequential amendments to other Acts

Briefing binder used by the Honourable Steven Guilbeault before the Standing Committee on Canadian Heritage, study of Bill C-10, An Act to amend the Broadcasting Act and to make related and consequential amendments to other Acts

Organization: Canadian Heritage | Patrimoine canadien
Post-Notice of Compliance (NOC) Changes: Safety and Efficacy Document

This guidance document applies to sponsors intending to make changes to new drugs that have received a NOC pursuant to section C.08.004 of the Food and Drug Regulations. These new drugs may include pharmaceuticals, biologics, and radiopharmaceuticals for human use and pharmaceutical and certain biotechnological products for veterinary use, including those submissions for which a NOC has been recommended but issuance of the NOC has been placed on hold.

Organization: Health Canada | Santé Canada
Post-Notice of Compliance (NOC) Changes: Framework Document

After a new drug as defined in section C.08.001 of the Food and Drug Regulations has been granted a Notice of Compliance (NOC), it is not uncommon for sponsors to make changes to the drug. A post-NOC change is any change that is made to a new drug that has received a NOC pursuant to section C.08.004 of the Food and Drug Regulations. Many of these changes may be made to improve the quality of the drug product or the efficiency of the manufacturing process, or they could be made for marketing considerations. Changes to the labelling of a drug product could include adding new indications, improving the management of risk for a product by adding warnings, limiting the target population or changing the dosage regime etc.

Organization: Health Canada | Santé Canada
Guidance Document: Post-Notice of Compliance (NOC) Changes: Safety and Efficacy Document (for pharmaceutical, biologic and radiopharmaceutical drugs for human use only)

This guidance document applies to sponsors intending to make changes to new drugs that have received a NOC pursuant to section C.08.004 of the Food and Drug Regulations. These new drugs may include pharmaceuticals, biologics, and radiopharmaceuticals for human use, including those submissions for which a NOC has been recommended but issuance of the NOC has been placed on hold.

Organization: Health Canada | Santé Canada
Guidance document: Post-Notice of Compliance (NOC) Changes: Framework Document (Pharmaceutical, biologic and radiopharmaceutical drugs for human use only)

A post-NOC change is any change that is made to a new drug that has received a NOC pursuant to section C.08.004 of the Food and Drug Regulations. Many of these changes may be made to improve the quality of the drug product or the efficiency of the manufacturing process, or they could be made for marketing considerations. Changes to the labelling of a drug product could include adding new indications, improving the management of risk for a product by adding warnings, limiting the target population or changing the dosage regime etc.

Organization: Health Canada | Santé Canada
Guidance Document: Determining Prescription Status for Human and Veterinary Drugs

Health Canada is publishing this document to be transparent about the principles and factors that it considers when deciding whether a drug would be best sold as a prescription or nonprescription product. This document is also designed to help the public, industry and healthcare professionals, including veterinarians, as well as other stakeholders, better understand and predict when a drug will be authorized as a prescription or nonprescription product.

Organization: Health Canada | Santé Canada
Guidance document: Product Monograph (2020)

The purpose of this guidance document is to assist sponsors in developing product monographs with acceptable format and content. Health Canada reviews the product monograph as part of the drug review process, as it forms an integral part of a new drug submission. A product monograph is intended to provide the necessary information for the safe and effective use of a new drug and also to serve as a standard against which all promotion and advertising of the drug can be compared.

Organization: Health Canada | Santé Canada
Guidance Document - Periodic Benefit-Risk Evaluation Report (PBRER) International Conference on Harmonisation (ICH) Topic E2C(R2)

The Periodic Benefit-Risk Evaluation Report (PBRER) described in this Guideline is intended to be a common standard for periodic benefit-risk evaluation reporting on marketed products (including approved drugs that are under further study) among the International Conference on Harmonisation (ICH) regions. This Guideline defines the recommended format and content of a PBRER and provides an outline of points to be considered in its preparation and submission.

Organization: Health Canada | Santé Canada
Notice - Adoption of the International Conference on Harmonisation (ICH) Guidance on Periodic Benefit Risk Evaluation Report - ICH Topic E2C(R2), as of March 1, 2013

Section C.01.018 of Division 1 of the Food and Drug Regulations requires the Market Authorization Holder (MAH) to analyze adverse drug reaction data and prepare an annual summary report. Annual summary reports are to be submitted when requested by Health Canada. In addition, Section C.01.018(4) requires that the MAH notify Health Canada without delay if there has been a significant change in what is known about the risks and benefits of the drug during the period covered by the report.

Organization: Health Canada | Santé Canada
Health Product Vigilance Framework

The Health Product Vigilance Framework is being developed to strengthen and modernize health product vigilance (PV) practices in Canada. Aligned with the Federal Regulatory Post-Market Surveillance Strategy, this framework will optimize resources by focusing on higher risk products through standardized prioritization policies and will implement a vigilance framework that manages risks consistently across product lines. It will emphasize industry's vigilance responsibilities, consistent with international harmonization objectives, wherever possible, and will integrate the use of product vigilance tools across product lines and throughout a product's lifecycle.

Organization: Health Canada | Santé Canada
Notice to Stakeholders: Updates to the Opioid Patient Information Handout

The purpose of this Notice is to notify stakeholders that Health Canada has made changes to the opioid patient information handout entitled “Opioid Medicines – Information for Patients and Families”. Canada's Food and Drug Regulations were recently amended to require that a warning sticker and patient information handout be provided to patients, at the time of sale, with all prescription opioids that appear in Part A of the “List of Opioids”.

Organization: Health Canada | Santé Canada
Opioid Warning Sticker and Patient Information Handout, and Risk Management Plans

Health Canada has identified the need for patients to receive clear information about the safe use of opioids and the risks associated with their use. As such, requirements have been added, under the Food and Drug Regulations, for a warning sticker and patient information handout to be provided with all prescription opioids that appear in Part A of the “List of Opioids”, at the time of dispensing.

Organization: Health Canada | Santé Canada